NCT06068985View on ClinicalTrials.gov

Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade

PHASE2RecruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

September 5, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2031

Conditions
Breast CancerHER2-positive Breast Cancer
Interventions
DRUG

PHESGO

Subcutaneous formulation with pertuzumab and trastuzumab.

Trial Locations (7)

40.170-110

RECRUITING

NOB - Núcleo de Oncologia da Bahia (Oncoclínicas), Salvador

30.360-680

RECRUITING

Oncocentro de Minas Gerais (Oncoclínicas), Belo Horizonte

90.610-000

RECRUITING

CPO - Centro de Pesquisa em Oncologia do Hospital São Lucas da PUCRS, Porto Alegre

13.083-881

RECRUITING

Faculdade de Ciências Médicas da Unicamp, Campinas

20.230-130

RECRUITING

INCA - Instituto Nacional de Câncer, Rio de Janeiro

04.538-135

RECRUITING

Centro Paulista de Oncologia (Oncoclínicas), São Paulo

14.784-400

RECRUITING

Hospital de Amor de Barretos, São Paulo

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

collaborator

Oncoclínicas

INDUSTRY

lead

Latin American Cooperative Oncology Group

OTHER